New Gene Target Could Improve Cholesterol Without Harming the Liver

Preclinical study identifies possible therapeutic target for cardiovascular risk factors that avoid the common problem of an increased risk of fatty liver disease.

9:38 AM

Author | Haley Otman

image of drawing of gene in blue ink on lined paper with lab note written on bottom right
Image by Stephanie King.

Medications to improve cholesterol and reduce cardiovascular risk factors can also put some patients at a higher risk for fatty liver disease or liver damage.

A new study from an international team of researchers points to a few genes as possible future targets to address cardiovascular risk without affecting the liver or causing other metabolic disorders.

"We know that some genes/proteins cause your cholesterol to either clog up your arteries or clog up your liver. We wanted to find genes that help people avoid it all: heart disease, diabetes and liver disease," explains co-corresponding author Cristen Willer, Ph.D., an associate professor of internal medicine, human genetics and computational medicine and bioinformatics, from the Michigan Medicine Frankel Cardiovascular Center.

Willer and colleagues identified 76 notable variants with potential, 11 of which were previously unreported. She says one in particular, known as ZNF529, was particularly interesting. People missing one copy of that gene had lower LDL cholesterol measures.

When the researchers in Y. Eugene Chen's Frankel CVC lab examined the gene in human liver cells, it had the same effect as a popular class of cholesterol-lowering drugs, PCSK9 inhibitors, that upregulate or activate the LDL receptor.

The researchers suggest future research to investigate inhibiting ZNF529. They also note this gene does not exist in mice, which limits the ability to study this gene in mice, but also suggests that mammals can survive without this gene.

"Understanding genes and genetic variants impacting the risk of CVD in the context of their biological roles will allow better choices for drug targets that will be more effective at preventing and treating disease, with fewer side effects," says co-corresponding author Chen, M.D., Ph.D., a professor of internal medicine, cardiac surgery, physiology, pharmacology and medicinal chemistry.

Paper cited: "Loss-of-function genomic variants highlight potential therapeutic targets for cardiovascular disease." Nature Communications. DOI: 10.1038/s41467-020-20086-3


More Articles About: Lab Notes Heart Disease Risk Factors Nonalcoholic fatty liver disease (NAFLD) Genetics Metabolism, Endocrinology & Diabetes Drug Discovery Cardiovascular: Preventive Cardiology
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories two hearts next to each other with small figure people inside and out of it
Health Lab
How neutrophil calprotectin unmasks future atherosclerotic heart disease risk
The immune system is showing evidence of playing a roll in the emergence of atherosclerotic cardiovascular disease. A rush of neutrophils, or immune cells to the site could be an explanation for how this condition forms as well as how to prevent this heart disease in the future.
blood vessel up close with red cells and yellow inside
Health Lab
Drug candidate successfully treats atherosclerosis, fatty liver disease in large mammals 
A compound that was previously found to treat severe fatty liver disease also reduces atherosclerosis, a primary driver of cardiovascular death, in non-human primates. The drug candidate was developed at the University of Michigan.
Michigan Medicine Presents... on dark blue background with two lights shining on the words
Michigan Medicine Presents
Episode 1: The Science of Bipolar Disorder
Bipolar disorder is more than just mood swings. It’s a journey marked by intense highs of mania and debilitating lows of depression. But within this condition exist millions of people who live unique lives. Today, we're going to talk to three clinical and research experts from the Heinz C. Prechter Bipolar Research Program at Michigan Medicine to learn more about the science of bipolar disorder—diagnostics, genetics, and decision-making. We'll be hearing from Dr. Melvin McInnis, director of the Prechter Program, Dr. Paul Jenkins, associate professor of pharmacology and associate director of the Prechter Program, and Dr. Chandra Sripada, professor of psychiatry and philosophy.
man standing smiling in hallway
Health Lab
Randy Seeley gets a lot of questions about GLP-1s. Here’s why
A Michigan Medicine Ph.D. researcher dissected bariatric surgery to understand how it actually works, contributing to obesity therapies that have given rise to drugs like Ozempic and Wegovy.
sperm moving to cell all blue and cell red
Health Lab
Battle of the sex chromosomes
A study from University of Michigan researchers has uncovered the mechanism behind the arms race for mouse X and Y bearing sperm to fertilize an egg.
two photos of the back of an eye
Health Lab
Managing your diabetes can help prevent associated vision loss
Diabetic retinal disease screening remains challenging because patients often do not have any symptoms in the early stages and, therefore, misunderstand the importance of regular screenings. In a recent publication Thomas Gardner discusses current screening recommendations and treatment options for DRD.